Evidence map›Paper›PMID 38903714›Full record

ArticleFrontiers in oncology2024

Case report: Sustained remission after combined sintilimab, anti-VEGF therapy, and chemotherapy in a patient with non-small cell lung cancer harboring acquired

Wanming He, Lihua Tong, Wen Yang, Yanling Yuan, Yu Li, Wubing Tang

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Wanming HeDepartment of Oncology, The Sixth Affiliated Hospital, School of Medicine, South China University of Technology, Foshan, China.
Lihua TongDepartment of Oncology, The Sixth Affiliated Hospital, School of Medicine, South China University of Technology, Foshan, China.
Wen YangDepartment of Oncology, The Sixth Affiliated Hospital, School of Medicine, South China University of Technology, Foshan, China.
Yanling YuanDepartment of Oncology, The Sixth Affiliated Hospital, School of Medicine, South China University of Technology, Foshan, China.
Yu LiDepartment of Oncology, The Sixth Affiliated Hospital, School of Medicine, South China University of Technology, Foshan, China.
Wubing TangDepartment of Oncology, The Sixth Affiliated Hospital, School of Medicine, South China University of Technology, Foshan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are highly effective against tumors harboring the T790M mutation. However, patients treated with these inhibitors ultimately develop resistance, and the most common mechanism is the emergence of the

Indexed as

anti-vascular endothelial growth factor therapygrowth factor receptornon-small cell lung cancerprogrammed cell death 1 inhibitortyrosine kinase inhibitors

Identifiers

PMID38903714
PMCPMC11187085

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.